Analysts Set Senseonics Holdings, Inc. (NYSE:SENS) PT at $22.70

Senseonics Holdings, Inc. (NYSE:SENS) has received an average rating of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, three have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $22.70.

SENS has been the topic of several analyst reports. HC Wainwright increased their target price on Senseonics to $18.50 and gave the stock a “buy” rating in a research report on Thursday, November 6th. TD Cowen lowered their price target on shares of Senseonics from $25.00 to $15.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Barclays reaffirmed an “overweight” rating and issued a $31.00 price objective (up previously from $1.50) on shares of Senseonics in a report on Wednesday, November 5th. Finally, Stifel Nicolaus began coverage on shares of Senseonics in a research note on Tuesday, October 21st. They set a “hold” rating and a $9.00 target price for the company.

Insider Activity

In other Senseonics news, Director Douglas A. Roeder acquired 15,000 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The stock was acquired at an average cost of $5.83 per share, with a total value of $87,450.00. Following the acquisition, the director directly owned 99,727 shares of the company’s stock, valued at $581,408.41. This represents a 17.70% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Frederick T. Sullivan bought 5,415 shares of the business’s stock in a transaction on Friday, November 7th. The shares were acquired at an average cost of $5.88 per share, for a total transaction of $31,840.20. Following the purchase, the chief financial officer directly owned 157,028 shares in the company, valued at $923,324.64. This represents a 3.57% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have acquired 30,415 shares of company stock valued at $184,790. Insiders own 3.60% of the company’s stock.

Institutional Trading of Senseonics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Elite Life Management LLC acquired a new position in shares of Senseonics in the second quarter worth about $36,000. Sio Capital Management LLC purchased a new stake in shares of Senseonics in the 2nd quarter valued at approximately $2,312,000. Charles Schwab Investment Management Inc. lifted its position in shares of Senseonics by 4.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,502,326 shares of the company’s stock valued at $2,298,000 after acquiring an additional 162,628 shares in the last quarter. Informed Momentum Co LLC acquired a new position in Senseonics in the 1st quarter worth approximately $559,000. Finally, Keynote Financial Services LLC grew its position in Senseonics by 1,120.2% during the 2nd quarter. Keynote Financial Services LLC now owns 208,285 shares of the company’s stock worth $99,000 after purchasing an additional 191,215 shares in the last quarter. 12.36% of the stock is currently owned by institutional investors.

Senseonics Stock Down 1.6%

Shares of Senseonics stock opened at $6.62 on Friday. The stock has a market capitalization of $270.49 million, a price-to-earnings ratio of -50.92 and a beta of 0.92. Senseonics has a twelve month low of $5.00 and a twelve month high of $28.00. The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17. The business’s 50 day simple moving average is $7.22 and its 200-day simple moving average is $8.94.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.